DexCom, Inc. (NASDAQ:DXCM) EVP Andrew K. Balo sold 3,200 shares of the company’s stock in a transaction on Monday, April 10th. The shares were sold at an average price of $78.19, for a total transaction of $250,208.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of DexCom, Inc. (NASDAQ:DXCM) traded down 0.72% on Thursday, hitting $76.22. 750,827 shares of the company traded hands. The firm’s 50-day moving average is $79.61 and its 200 day moving average is $75.31. DexCom, Inc. has a 1-year low of $57.68 and a 1-year high of $96.38. The firm’s market capitalization is $6.46 billion.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, February 28th. The medical device company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. The company earned $171.20 million during the quarter, compared to analyst estimates of $167.51 million. DexCom had a negative net margin of 10.64% and a negative return on equity of 23.61%. DexCom’s quarterly revenue was up 30.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.02 earnings per share. On average, analysts anticipate that DexCom, Inc. will post ($0.54) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was posted by sleekmoney and is the sole property of of sleekmoney. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://sleekmoney.com/dexcom-inc-dxcm-evp-andrew-k-balo-sells-3200-shares/1739223.html.
A number of equities research analysts recently commented on DXCM shares. Canaccord Genuity reiterated a “buy” rating on shares of DexCom in a report on Tuesday, January 10th. Zacks Investment Research upgraded shares of DexCom from a “sell” rating to a “hold” rating in a report on Monday, January 9th. Oppenheimer Holdings Inc. reiterated a “buy” rating and set a $98.00 price target on shares of DexCom in a report on Friday, January 13th. Morgan Stanley lowered shares of DexCom from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $87.00 to $66.00 in a report on Tuesday, January 3rd. Finally, BTIG Research restated a “buy” rating and issued a $92.00 price objective on shares of DexCom in a report on Friday, January 13th. Three research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $92.27.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Bremer Trust National Association purchased a new position in DexCom during the first quarter valued at approximately $302,000. Capstone Asset Management Co. purchased a new position in DexCom during the first quarter valued at approximately $213,000. Chevy Chase Trust Holdings Inc. purchased a new position in DexCom during the first quarter valued at approximately $3,600,000. Highbridge Capital Management LLC purchased a new position in DexCom during the fourth quarter valued at approximately $2,983,000. Finally, Teachers Advisors LLC raised its position in DexCom by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 184,560 shares of the medical device company’s stock valued at $11,018,000 after buying an additional 7,050 shares during the last quarter.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/dexcom-inc-dxcm-evp-andrew-k-balo-sells-3200-shares/1739223.html
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.